Clinipace Worldwide acquires Regulus Pharmaceutical Consulting

Tuesday, March 1, 2011 11:56 AM

Clinipace Worldwide, a global digital CRO based in Morrisville, N.C., has acquired Regulus Pharmaceutical Consulting, a regulatory affairs and quality assurance consultancy based in Boulder, Colo.  

With this acquisition, Clinipace has expanded its regulatory and strategic development expertise and increased its staff by 20%. The Regulus team will remain in Colorado with the same management structure and personnel and will operate as the regulatory affairs, strategic development and quality assurance consultancy division of Clinipace.  

Brenda Fielding, Regulus president, will become executive vice president of regulatory affairs for Clinipace. Prior to Regulus, she held senior management positions in U.S. pharmaceutical and biotechnology companies, involved in clinical development over a range of therapeutic areas including oncology, anti-infectives, immunotherapeutics and ophthalmology.

With specific expertise in oncology, among other therapeutic areas, Clinipace has managed over 200 contract research and regulatory projects.  Headquartered in Research Triangle Park, N.C., it also has operations in Overland Park, Kan., Boulder, Colo., and South American operations in Brazil, Argentina and Peru.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs